For hereditary hemophilia, prophylactic factor replacement remains the standard; however, therapies such as Emicizumab—a bispecific antibody that bridges activated factor IX (FIXa) and factor X (FX) to restore the missing function of activated factor VIII (FVIIIa)—have transformed prophylaxis for Hemophilia A, especially in patients with inhibitors [45]. This evidence concerns the gene F9 and hemophilia A.